Peptides can offer the versatility needed for a successful oncology drug discovery approach. Peptide–drug conjugates (PDCs) are an emerging targeted therapeutic that present increased tumour penetration and selectivity.
What’s more, Peptides are recognized for being highly selective and efficacious and, at the same time, relatively safe and well tolerated. Consequently, there is an increased interest in peptides in pharmaceutical research and development (R&D), and approximately 140 peptide therapeutics are currently being evaluated in clinical trials.
The top-selling peptide drug for metabolic diseases is liraglutide, a glucagon-like peptide (GLP-1). Popular peptide drugs, including leuprolide, goserelin, and the somatostatin analogs octreotide.
What’s our advantages on Peptides drug?
Our workflow for peptide drug development starts with extensive design and engineering for the optimization of multiple parameters. Our integrated platform team employs advanced synthetic strategies, high throughput screening, computer-aided drug design, phage display and NMR structural studies to optimize activity, efficacy and selectivity.
Our team is eager to support basic research studies and target validation. We provide FDA approved peptide drugs tools such as long and difficult peptide sequences, small proteins, labeled peptides, complex peptides and proteins with post translational modifications.